Cerus Reports Positive Topline Results From Phase 3 RedeS Trial
Cerus announced positive topline results from its Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells.
Story updates
09:00:44 PM UTC
SquawkNews
Cerus said its Phase 3 RedeS trial met the primary efficacy endpoint, demonstrating non-inferiority of INTERCEPT RBCs versus conventional RBCs on adjusted hemoglobin increment. The system remains investigational in the U.S.; the FDA has not reviewed the final study report.Material DetailsContext by…
09:01:16 PM UTC
SquawkNews
CERUS- MET PRIMARY EFFICACY ENDPOINT DEMONSTRATING NON-INFERIORITY OF INTERCEPT RBCS TO CONVENTIONAL
09:25:01 PM UTC
SquawkNews
Cerus Corp NASDAQ:CERS said on Monday a late-stage study showed that red blood cells treated with its blood-safety technology performed as well as conventional red blood cells in patients requiring transfusions.Cerus' Intercept technology is designed to reduce the risk of viruses, bacteria and othe…